PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial
RM Stone, J De Angelo, I Galinsky… - Annals of …, 2004 - pubmed.ncbi.nlm.nih.gov
PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial PKC 412 FLT3 inhibitor therapy
in AML: results of a phase II trial Ann Hematol. 2004:83 Suppl 1:S89-90. doi:
10.1007/s00277-004-0850-2. Authors RM Stone 1 , J De Angelo, I Galinsky, E Estey, V Klimek, W
Grandin, D Lebwohl, A Yap, P Cohen, E Fox, D Neuberg, J Clark, DG Gilliland, JD Griffin
Affiliation 1 Dana-Farber Cancer Institute, Boston, MA, USA. PMID: 15124689 DOI:
10.1007/s00277-004-0850-2 No abstract available Publication types Clinical Trial Clinical Trial …
in AML: results of a phase II trial Ann Hematol. 2004:83 Suppl 1:S89-90. doi:
10.1007/s00277-004-0850-2. Authors RM Stone 1 , J De Angelo, I Galinsky, E Estey, V Klimek, W
Grandin, D Lebwohl, A Yap, P Cohen, E Fox, D Neuberg, J Clark, DG Gilliland, JD Griffin
Affiliation 1 Dana-Farber Cancer Institute, Boston, MA, USA. PMID: 15124689 DOI:
10.1007/s00277-004-0850-2 No abstract available Publication types Clinical Trial Clinical Trial …
